Powered by

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta(R) (ofatumumab) in newly diagnosed treatment-naive adults with relapsing multiple sclerosis

Sep 11, 2020 - Thomson Reuters ONE

- New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naive patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide1

- Additional safety data in over 1,800 patients who continued Kesimpta treatment or switched therapy from previous studies reinforce the favorable safety profile of Kesimpta in patients with relapsing forms of multiple sclerosis ...